Image: Fierce PharmaMerck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens
• Merck & Co. is considering the use of molnupiravir, an antiviral drug previously authorized for COVID-19 treatment, to combat a worsening Ebola outbreak in central Africa. • The move comes as governments and health authorities struggle to respond to the escalating public health crisis in the region. • Repurposing an existing antiviral could provide a faster therapeutic option for patients as the outbreak intensifies.
fiercepharma.com